Skip to Content

ValueTheMarkets Podcast 032 – with Maurice Treacy, Chief Commercial Officer of Open Orphan (ORPH)

Today’s guest on the ValueTheMarkets podcast is Maurice Treacy, Chief commercial officer of Open Orphan (LSE:ORPH) The company is focused on rare disease and orphan drug pharma services and aims to achieve rapid growth through the acquisition of smaller, high-margin pharma service providers. Following on from our earlier podcast with CEO, Cathal Friel, Maurice focusses on discussing the technical side of the business.

One of the key offerings the firm is developing is the first Genomic Health Database. Maurice gives further details and outlines the need for the database as well as highlighting the opportunity this presents to Open Orphan.

All opinions expressed are those of ValueTheMarkets and the respective guests unless otherwise stated and should not be construed as investment advice or a recommendation to buy shares in any featured Company. Listeners are advised to do their own extensive research before buying shares which, as with all small-cap exploration stocks, should be viewed as high risk. Investors should also seek the advice of a qualified investment adviser or stockbroker as they deem appropriate. and Dynamic Investor Relations Ltd are not responsible for the content or accuracy of this article.  News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

  • Stuart Langelaan does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the piece.
  • Stuart Langelaan has been paid to produce this piece by the company or companies mentioned above.
  • Dynamic Investor Relations Ltd, the owner of, has been paid for the production this piece by the company or companies mentioned above.

Related Articles


teathers app screenshot

App Empowering Private Investors

Crowd Equity for Placings, IPOs and Live Market Blockbuilds, designed to give provate investors access to placements and Intial Public Offerings (IPOs), predominantly on the London Stock Exchange’s Alternative Investment Market (AIM).